Xeltis announced today that is planning to accelerate its clinical trial program for three restorative devices in parallel. CEO Eliane Schutte provided a sneak preview on Xeltis’ plans to an audience of investors and medtech companies at the Medtech and Diagnostics Forum organised by the investment bank Canaccord Genuity Capital Markets.
Xeltis currently has three restorative devices in clinical trial phase, including aXess – a restorative access graft for dialysis; XABG – which is a coronary artery bypass graft; and its pulmonary heart valve, which was the first ever synthetic valve to enter a pivotal trial (Xplore2/Pivotal) in July this year.
“It is a very exciting phase for Xeltis, with excellent, promising preclinical outcomes presented and published on the vascular front – raising significant expectations in the scientific and medical community – and an upcoming acceleration on the clinical front. More news on the trial programs will be announced next week,” anticipated Schutte at the meeting.
